Angus Liu

Washington, D.C., United States

Deputy Editor at Fierce Biotech

Deputy Editor at FiercePharma

Biopharma follower @FiercePharma & @FierceBiotech. Medill MSJ 16

Featured in: Favicon

fiercebiotech.com Favicon

fiercepharma.com Favicon

geneticliteracyproject.org Favicon

friendsofcancerresearch.org Favicon

newsbreak.com Favicon

pharmaceuticalintelligence.com Favicon

einnews.com

Articles

Fierce Pharma Asia—AZ-CSPC deal; FDA's American cell shipping ban; China's trial review acceleration plan

1 week ago | fiercepharma.com | Angus Liu

AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. Chinese regulators are proposing to shorten clinical trial review times for novel medicines. And more. 1.
Bavarian Nordic sells FDA priority review voucher from chikungunya vaccine approval for $160M

1 week ago | fiercepharma.com | Angus Liu

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. Bavarian Nordic has reached an agreement to sell a priority review voucher (PRV) gained from Vimkunya’s approval to an unnamed buyer for $160 million, the Danish company said Wednesday. The FDA awarded the PRV under its tropical disease program.
Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others

1 week ago | fiercepharma.com | Angus Liu

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a legislative loophole that drugmakers are allegedly lobbying to retain. In letters (PDF) published Tuesday, Sen.
In setback for biopharma, Senate version of Trump's tax bill drops Orphan Cures Act

1 week ago | fiercepharma.com | Angus Liu

The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend an Inflation Reduction Act (IRA) provision currently affecting treatments for rare diseases. The Senate version of the One Big Beautiful Bill Act, unveiled Monday, has dropped what’s known as the Orphan Cures Act. The bipartisan Orphan Cures Act would allow drugs with multiple rare disease indications to be exempt from Medicare’s drug price negotiations under the IRA.
China proposes shorter clinical trial reviews in efforts to accelerate drug development

1 week ago | fiercebiotech.com | Angus Liu

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time that regulators take to review clinical trials. In a draft policy posted (Chinese) Monday, China’s National Medical Products Administration (NMPA) is proposing to cut the clinical trial review waiting period for novel medicines to 30 working days, down from the current 60 working days.
Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients

1 week ago | fiercepharma.com | Angus Liu

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed in March, the patient died after developing acute liver failure (ALF) and was non-ambulatory, meaning the individual was no longer able to walk independently because of progression of Duchenne.
The 10 highest-paid Big Pharma CEOs of 2024

1 week ago | fiercepharma.com | Fraiser Kansteiner |Zoey Becker |Eric Sagonowsky |Angus Liu
Merck's Keytruda wins breakthrough head and neck cancer nod around surgery but with a limitation

2 weeks ago | fiercepharma.com | Angus Liu

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes with a limitation. For the perioperative head and neck squamous cell carcinoma (HNSCC) indication where Keytruda is used both before and after surgery, the PD-1 inhibitor is only allowed in patients whose tumors express PD-L1 at a combined positive score of at least 1.
Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN Entresto feud

2 weeks ago | fiercepharma.com | Angus Liu

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease immunoglobulin A nephropathy (IgAN). Novartis is pressing for a speedy ruling in its Entresto patent litigation against MSN Pharmaceuticals. 1.
Bristol Myers CEO stays bullish on Cobenfy despite trial flop

2 weeks ago | fiercepharma.com | Angus Liu

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem. The drug recently failed as an adjunctive treatment in a phase 3 trial for inadequately controlled schizophrenia, and, as Goldman Sachs analyst Asad Haider noted, new-to-brand prescription growth appears to be moderating as the second quarter nears its end. But Bristol Myers CEO Chris Boerner and Chief Commercialization Officer Adam Lenkowsky don’t see things that way.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 757
Tweets: 107
DMs Open: No

Angus Liu @Angus_Fierce

18 Feb 25

Was just wondering what Vivek's been up to.

The Hill @thehill

Vivek Ramaswamy set to launch Ohio governor bid on Feb. 24 https://t.co/cXGHsIE7lY

Angus Liu @Angus_Fierce

27 Sep 24

... Yunchan Lim ... Rach 2 ... 😭

Twitter User @user

Angus Liu @Angus_Fierce

8 Sep 24

RT @FiercePharma: Akeso, Summit's ivonescimab crushes Merck's Keytruda in China study, signaling potential new standard of care in lung can…

Angus Liu

Articles

Fierce Pharma Asia—AZ-CSPC deal; FDA's American cell shipping ban; China's trial review acceleration plan

Bavarian Nordic sells FDA priority review voucher from chikungunya vaccine approval for $160M

Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others

In setback for biopharma, Senate version of Trump's tax bill drops Orphan Cures Act

China proposes shorter clinical trial reviews in efforts to accelerate drug development

Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients

The 10 highest-paid Big Pharma CEOs of 2024

Merck's Keytruda wins breakthrough head and neck cancer nod around surgery but with a limitation

Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN Entresto feud

Bristol Myers CEO stays bullish on Cobenfy despite trial flop

Contact details

Emails

Socials & Sites

X (formerly Twitter)